ProteomEdge provides proprietary mass spectrometry platforms for precise, absolute protein quantification of clinically relevant targets.
ProteomEdge has raised $858K in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in March 2026.
ProteomEdge's investors include Navigare Ventures.
ProteomEdge is headquartered in Stockholm, Sweden.
ProteomEdge provides proprietary mass spectrometry platforms for precise, absolute protein quantification of clinically relevant targets.
ProteomEdge is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ProteomEdge — Funding & Investors." VCBacked, March 25, 2026, https://www.vcbacked.co/company/proteomedge. Accessed September 30, 2026.
VCBacked. (2026). ProteomEdge — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/proteomedge
{{cite web |title=ProteomEdge — Funding & Investors |url=https://www.vcbacked.co/company/proteomedge |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated